LivaNova (NASDAQ:LIVN) Rating Increased to Buy at StockNews.com

StockNews.com upgraded shares of LivaNova (NASDAQ:LIVN) from a hold rating to a buy rating in a report published on Thursday morning.

Several other equities research analysts have also commented on the stock. Mizuho reiterated a buy rating and issued a $75.00 price objective on shares of LivaNova in a research report on Wednesday, March 27th. Robert W. Baird boosted their price objective on shares of LivaNova from $56.00 to $62.00 and gave the stock a neutral rating in a research report on Thursday, February 22nd. Needham & Company LLC reiterated a buy rating and issued a $72.00 price objective on shares of LivaNova in a research report on Wednesday, March 20th. Finally, Barclays upped their target price on shares of LivaNova from $57.00 to $61.00 and gave the company an equal weight rating in a report on Monday, February 26th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of Moderate Buy and a consensus price target of $64.40.

LivaNova Stock Performance

NASDAQ:LIVN opened at $55.53 on Thursday. The company has a quick ratio of 2.51, a current ratio of 2.95 and a debt-to-equity ratio of 0.44. LivaNova has a fifty-two week low of $42.75 and a fifty-two week high of $59.86. The stock has a market cap of $3.00 billion, a PE ratio of 173.54 and a beta of 0.89. The firm’s fifty day simple moving average is $54.13 and its 200-day simple moving average is $50.64.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, February 21st. The company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.77 by $0.10. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The business had revenue of $310.10 million for the quarter, compared to analyst estimates of $287.65 million. During the same period in the previous year, the firm earned $0.81 EPS. The business’s revenue for the quarter was up 12.8% compared to the same quarter last year. Analysts expect that LivaNova will post 3.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Primecap Management Co. CA lifted its holdings in LivaNova by 7.3% in the 3rd quarter. Primecap Management Co. CA now owns 5,785,360 shares of the company’s stock valued at $305,930,000 after purchasing an additional 395,940 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of LivaNova by 6.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,770,277 shares of the company’s stock valued at $93,612,000 after acquiring an additional 100,133 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of LivaNova by 6.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,241,985 shares of the company’s stock valued at $64,262,000 after acquiring an additional 74,067 shares during the last quarter. Greenlight Capital Inc. increased its stake in shares of LivaNova by 3.5% during the 4th quarter. Greenlight Capital Inc. now owns 1,229,316 shares of the company’s stock valued at $63,605,000 after acquiring an additional 42,040 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its stake in shares of LivaNova by 96.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 916,632 shares of the company’s stock valued at $48,471,000 after acquiring an additional 449,136 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.